Device Trial Radar · NCT06911632
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
900
Planned (sponsor's estimate)
Start
Jul 23, 2025
Primary completion
May 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Tempus AINot on our public-company list
- Sponsor type
- Industry
- Collaborators
- United Therapeutics
- First posted
- Apr 4, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.
Conditions
- Pulmonary Hypertension
- Interstitial Lung Disease (ILD)
Interventions
ECG-based AI Device - Results Returned to InvestigatorDevice
An ECG-based AI device that predicts undiagnosed PH using data from a 12-lead ECG. Device results will be returned to the Investigators.
Echocardiogram and Right Heart CatheterizationProcedure
Echocardiogram- an ultrasound study of the heart and Right Heart Catheterization- a procedure to measure pressures in the heart
ECG-based AI Device - Results Not Returned to InvestigatorDevice
An ECG-based AI device that predicts undiagnosed PH using data from a 12-lead ECG. Device results will not be returned to the Investigators.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants receiving a new diagnosis of PH within the High risk Device group compared to the High risk Control group.Time frame: Through study completion, approximately 6 months
Locations
41 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Banner University Medical Center
Phoenix, Arizona · Recruiting
Dignity Health - St. Joseph's Hospital and Medical Center-Norton Thoracic Institute
Phoenix, Arizona · Recruiting
38 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.